Corcept Therapeutics does not pay a cash dividend to its shareholders, maintaining a strategic corporate policy of retaining all earnings and free cash flows to fund ongoing research and development, advance its clinical drug pipeline, and support aggressive share repurchase programs. Consequently, its dividend yield remains at zero percent, which is typical for biotechnology and commercial-stage pharmaceutical enterprises prioritizing long-term pipeline expansion.